| Number (%) | Univariate analysis | |||
---|---|---|---|---|---|
3Y–PFS (%) | P value | 3Y–OS (%) | P value | ||
Gender | |||||
 Male | 312(55.3%) | 74.4% | 0.101 | 80.4% | 0.017 |
 Female | 252(44.7%) | 78.0% |  | 92.0% |  |
Age, years | |||||
  ≤ 60 | 381(67.6%) | 78.6% | 0.062 | 88.3% | 0.002 |
  > 60 | 183(32.4%) | 70.2% |  | 72.1% |  |
Ann Arbor stage | |||||
 I,II | 310(55.0%) | 85.6% | <0.001 | 91.8% | <0.001 |
 III,IV | 254(45.0%) | 64.4% |  | 72.8% |  |
LDH(U/L) | |||||
  ≤ 245 | 337(59.8%) | 84.8% | <0.001 | 91.6% | <0.001 |
  > 245 | 227(40.2%) | 62.8% |  | 70.6% |  |
ECOG PS | |||||
 0,1 | 466(82.6%) | 79.9% | <0.001 | 86.3% | <0.001 |
  ≥ 2 | 98(17.4%) | 57.2% |  | 68.5% |  |
Extranodal sites | |||||
  ≤ 1 | 416(73.8%) | 80.3% | <0.001 | 88.2% | 0.017 |
  > 1 | 148(26.3%) | 62.5% |  | 67.2% |  |
IPI | |||||
 L | 309(54.8%) | 94.1% | <0.001 | 87.6% | <0.001 |
 LI | 96(17.0%) | 84.5% |  | 72.5% |  |
 HI | 96(17.0%) | 64.3% |  | 57.0% |  |
 H | 63(11.2%) | 55.4% |  | 51.5% |  |
CRP (mg/L) | |||||
  ≤ 8.6 | 357(63.3%) | 83.7% | <0.001 | 91.2% | <0.001 |
  > 8.6 | 207(36.7%) | 64.0% |  | 70.9% |  |
Albumin levels (g/L) | |||||
  < 41.5 | 266(47.2%) | 67.0% | <0.001 | 72.8% | <0.001 |
  ≥ 41.5 | 298(52.8%) | 83.9% |  | 92.3% |  |
LMR | |||||
  ≤ 2.7 | 348(61.7%) | 63.2% | <0.001 | 70.0% | <0.001 |
  > 2.7 | 216(38.3%) | 83.9% |  | 91.4% |  |
NLR | |||||
  ≤ 4.6 | 436(77.3%) | 82. 3% | <0.001 | 89.0% | <0.001 |
  > 4.6 | 128(22.7%) | 60.9% |  | 68.8% |  |
PLR | |||||
  ≤ 187.4 | 389(69.0%) | 81.2% | <0.001 | 87.9% | <0.001 |
  > 187.4 | 175(31.0%) | 69.1% |  | 76.6% |  |
Fibrinogen levels (g/L) | |||||
  ≤ 3.8 | 359(63.6%) | 82.9% | 0.001 | 88.3% | 0.001 |
  > 3.8 | 205(36.4%) | 68.8% |  | 76.2% |  |